TradeSmart-Stocks

$ABVC DUE DILLIGANCE Top overnight gap candidate🚨 Float: 8.68M Short Percentage: 15% Insider Ownership: 17.5% Insider Transactions: None Recently Past Events: 1-) Acquiring of TT Life Company that is worth $8.3M. This acquisition strengthens ABVC's portfolio and enables them for robust development and integration of AI in their development pipeline. 2-) Global Licensing Definitive Agreement for the treatment of NSCLC on April 17, "ABVC and its affiliate are set to receive an aggregate license fee of $12,500,000 in the form of cash or shares... within 30 days of executing the agreement" Context: ABVC should be getting the first round of funding in the next 1 month by May17th. 3-) ABVC Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M ( April 10th ) Context: 30 Days for this one as well, we should be expecting money coming in by May 10th. 4-) ABVC Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M Summary: With the three licensing agreement deals, we see a massive increase in revenue: 12,500,000 + 30,000,000 + 50,000,000 = $92,500,000 (Just in the month of may), puts ABVC in a very strong cash position, through which they can fund their robust pipeline inventory. Along with the licensing agreement deals, ABVC has many upcoming Catalysts, that are already in Phase 2 and 3 by end of first half 2024.(shown in pictures below)